New alliance will target major risk factor for Alzheimer's

Share this article:

A new collaboration will see four leading academic research laboratories working with AstraZeneca to study a major risk factor for Alzheimer's disease. Steven Paul, M.D., of Weill Cornell Medical College and AstraZeneca jointly announced the A5 Alliance. Collectively, the alliance will examine the apolipoprotein E4 genotype (ApoE). “We are convinced that ApoE represents a major piece of the Alzheimer's disease puzzle,” Paul noted. Additional members include David Holtzman, M.D. of Washington University in St. Louis, Peter Davies, Ph.D., of The Feinstein Institute for Medical Research and Cheryl Wellington, Ph.D., of the University of British Columbia.

Share this article:
close

Next Article in Products

More in Products

Aviv REIT offers public stock

Aviv REIT announced the public offering of 8 million shares of common stock at a public offering price of $24.10 per share.

NCAL unveils 2014 Assisted Living Week logo

NCAL unveils 2014 Assisted Living Week logo

The National Center for Assisted Living is encouraging communities to use the 2014 "The Magic of Music" logo to celebrate National Assisted Living Week.

New healthcare educational catalog available

New healthcare educational catalog available

Nasco has released its 2014-2015 Health Care Educational Materials catalog, which focuses on training with versatile medical procedure simulators.